Beyond the Treatment Peak: Why We Need Pharmacotherapeutic Follow-Up Protocols for the Withdrawal of Metabolic Weight-Loss Therapies

The advent of next-generation incretin therapies has revolutionized the management of obesity and cardiometabolic diseases, achieving significant and historically unprecedented weight reductions in pharmacotherapy. However, the commercial appeal and aesthetic pressure from social media have transformed these medications into short-term body remodeling tools, creating a false perception of a "definitive solution" and diverting attention from the need for long-term management. This opinion article examines the global impact of these therapies and critiques the lack of clinical guidelines addressing the postachievement phase of therapeutic goals. Abrupt discontinuation or loss of follow-up triggers compensatory neuroendocrine adaptations, resulting in weight cycling and the development of sarcopenic obesity due to disproportionate regain of visceral fat. It is concluded that obesity management should not stop at the peak phase of treatment. The implementation of structured deprescribing protocols (gradual tapering) co-managed by the endocrinologist and the clinical pharmacist, integrated into the interdisciplinary team, is advocated, transforming discontinuation into an active and safe step for the continuous maintenance of cardiometabolic health.

Authors

Institutions

Publication Details

Journal
Diabetes & Obesity International Journal
Published
2026-11-17
DOI
https://doi.org/10.23880/doij-16000302
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Beyond the Treatment Peak: Why We Need Pharmacotherapeutic Follow-Up Protocols for the Withdrawal of Metabolic Weight-Loss Therapies

João Pedro FD
3 links
Diabetes & Obesity International Journal
Pharmacology and Obesity Treatment
article

Beyond the Treatment Peak: Why We Need Pharmacotherapeutic Follow-Up Protocols for the Withdrawal of Metabolic Weight-Loss Therapies

João Pedro FD
article en

Abstract

The advent of next-generation incretin therapies has revolutionized the management of obesity and cardiometabolic diseases, achieving significant and historically unprecedented weight reductions in pharmacotherapy. However, the commercial appeal and aesthetic pressure from social media have transformed these medications into short-term body remodeling tools, creating a false perception of a "definitive solution" and diverting attention from the need for long-term management. This opinion article examines the global impact of these therapies and critiques the lack of clinical guidelines addressing the postachievement phase of therapeutic goals. Abrupt discontinuation or loss of follow-up triggers compensatory neuroendocrine adaptations, resulting in weight cycling and the development of sarcopenic obesity due to disproportionate regain of visceral fat. It is concluded that obesity management should not stop at the peak phase of treatment. The implementation of structured deprescribing protocols (gradual tapering) co-managed by the endocrinologist and the clinical pharmacist, integrated into the interdisciplinary team, is advocated, transforming discontinuation into an active and safe step for the continuous maintenance of cardiometabolic health.

Diabetes & Obesity International JournalVol. 11(2)
Grupo Santa Casa de Belo Horizonte (BR)
Good health and well-being
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon